Milestones
2024.11 — BioNTech to acquire Biotheus to boost oncology strategy
BioNTech to acquire Biotheus to boost oncology strategy
2024.07 — Nantong Manufacturing Base completed and put into production; PM8002：Approved for Phase III Registrationial Trial（SCLC）
Nantong Manufacturing Base completed and put into production; PM8002：Approved for Phase III Registrationial Trial（SCLC）
2024.04 — PM8002：Approved for Phase III Registrationial Trial（TNBC）
PM8002：Approved for Phase III Registrationial Trial（TNBC）
2024.03 — PM8002：Granted “Breakthrough-Therapy-Designated Drugs”by NMPA; Expanded Partnership with Hansoh Pharma for PM1080
PM8002：Granted “Breakthrough-Therapy-Designated Drugs”by NMPA; Expanded Partnership with Hansoh Pharma for PM1080
2024.02 — Strategic cooperation with Bitterroot Bio
Strategic cooperation with Bitterroot Bio
2023.11 — Entered into Strategic Partnership with BioNTech for PM8002
Entered into Strategic Partnership with BioNTech for PM8002
2023.07 — Strategic Research Collaboration and Worldwide License Agreement with BioNTech
Strategic Research Collaboration and Worldwide License Agreement with BioNTech
2022.11 — Entered into a license and collaboration agreement with Hansoh Pharma for PM1080
Entered into a license and collaboration agreement with Hansoh Pharma for PM1080
2022.09 — PM1009: IND approval for FIH phase I study
PM1009: IND approval for FIH phase I study
2022.04 — PM1021: IND filing for phase I study in Australia
PM1021: IND filing for phase I study in Australia
2022.03 — PM1032 & PM1015: IND approval for FIH Phase I studies
PM1032 & PM1015: IND approval for FIH Phase I studies
2022.02 — PM8002: entered clinical phase II studies
PM8002: entered clinical phase II studies
2022.01 — PM1022: IND approval for FIH phase I study
PM1022: IND approval for FIH phase I study
2021.12 — PM8001: obtained FDA approval for global multi-center phase II clinical trial
PM8001: obtained FDA approval for global multi-center phase II clinical trial
2021.09 — PM1003: IND approval for FIH phase I study
PM1003: IND approval for FIH phase I study
2021.07 — PM8003: IND approval for FIH phase I study
PM8003: IND approval for FIH phase I study
2021.04 — PM8001: entered clinical phase IIa studies
PM8001: entered clinical phase IIa studies
2021.03 — Round B financing; PM8002: the first subject was enrolled
Round B financing; PM8002: the first subject was enrolled
2020.12 — Biotheus (Nantong) establishment
Biotheus (Nantong) establishment
2020.11 — Biotheus core team awarded as "Zhuhai City Innovation and Entrepreneurship Team"
Biotheus core team awarded as "Zhuhai City Innovation and Entrepreneurship Team"
Copyright © 2022 Biotheus Inc. All Rights Reserved 粤ICP备2021122492号